57 results about "Treatment glaucoma" patented technology

A system for preparation of an implant and ab interno insertion of the implant into an eye including a handle having one or more actuators and an elongated shaft having an outer sheath and an elongate member positioned within a lumen of the tubular outer sheath. The system includes a recess sized for holding a patch of material fixed relative to the handle and a cutting member movable relative to the handle and to the recess. The cutting member cuts the patch of material into an implant as the cutting member moves towards a cutting configuration. The implant, once cut, is axially aligned with the lumen of the tubular outer sheath. The inner elongate member is movable relative to the tubular outer sheath to advance the implant into a deployment position in the lumen of the tubular outer sheath for delivery into the eye. Related devices and methods are provided.

Transcorneal and fiberoptic laser delivery systems and methods for the treatment of eye diseases wherein energy is delivered by wavelengths transparent to the cornea to effect target tissues in the eye for the control of intraocular pressure in diseases such as glaucoma by delivery systems both external to and within ocular tissues. External delivery may be affected under gonioscopic control. Internal delivery may be controlled endoscopically or fiberoptically, both systems utilizing femtosecond laser energy to excise ocular tissue. The femtosecond light energy is delivered to the target tissues to be treated to effect precisely controlled photodisruption to enable portals for the outflow of aqueous fluid in the case of glaucoma in a manner which minimizes target tissue healing responses, inflammation and scarring.

The invention relates generally to medical devices and methods for reducing the intraocular pressure in an animal eye and, more particularly, to stent type devices for permitting aqueous outflow from the eye's anterior chamber and associated methods thereof for the treatment of glaucoma. Some aspects provide a self-trephining glaucoma stent and methods thereof which advantageously allow for a “one-step” procedure in which the incision and placement of the stent are accomplished by a single device and operation. This desirably allows for a faster, safer, and less expensive surgical procedure.

The present disclosure describes an optical probe for applying a laser light to at least the flat portion of the ciliary body and optionally other areas, such as the trabecular mesh, the ciliary crown and / or the ciliary sulcus of the eye, the present invention relates to methods, such as for treating glaucoma, reducing intraocular pressure (IOP), improving the outflow of aqueous humor from the eye, and / or reducing the accumulation of aqueous humor within the eye. The optical probe may be adapted for simultaneous treatment of a plurality of different regions, tissues, or eye bodies of the eye, or for sequential treatment of a plurality of different regions, tissues, or eye bodies of the eye.

In specific embodiments, provided is a material for preventing adhesion of membranes in an ophthalmic surgery for treatment of glaucoma or the like without using mitomycin-C or the like. Particularly provided is such material, which is easy to handle and has no risk of histolysis or infections. In a production method of a preferred embodiment, prepared are: aldehyde-modified dextran (first reactant) having weight-average molecular weight of 10,000-5,000,000 and introduced aldehyde group-per-anhydrous glucose unit (mol / AGU) of 0.4-0.7; and succinic anhydride-added poly-L-lysine (second reactant) having weight-average molecular weight of 1000-100,000 and having residual amino group ratio of 80-99%; then, they are mixed together so that aldehyde group-to-amino group molar ratio becomes 0.9-1.1 and are reacted in presence of water so that polymer concentration becomes 8-20%; and a hydrogel produced by the reaction, or a suspension before gelation, is freeze-dried to produce a porous sheet having a thickness of 0.1-0.8 mm.

A shunt for treating glaucoma that includes a silicone rubber duct for diverting aqueous humor from a chamber of a patient's eye and a fixation body frictionally located on the duct in an arrangement permitting sliding displacement of the fixation body, for fixing and sealing the duct within scleral tissue surrounding the eye. The duct has a rigid proximal portion having a proximal end and a deformable distal portion locatable in the scleral channel and having a distal end. The distal portion is severable, allowing a surgeon to cut the distal portion to a desired length corresponding to the anatomical dimensions of the patient's eye and a required bleb position. The proximal portion has a capillary lumen having a diameter which is smaller than the diameter of a lumen of the distal portion, thereby reducing a flow rate of aqueous humor along the capillary lumen.

Pharmaceutical compositions, methods for treating various issues of the eyes, and methods of preparing such compositions are described. These pharmaceutical compositions may be for treating glaucoma, in preparation of eye surgery, during eye surgery, various post-op care (e.g., after cataract surgery, laser eye surgery, and the like), for treating dry eyes, and / or for promoting eyelash growth. These pharmaceutical compositions may comprise such active ingredients (APIs) as: timolol, latanoprost, brimonidine tartrate, dorzolamide, moxifloxacin HCl, dexamethasone PO4, phenylephrine HCl, lidocaine HCl, ketorolac tromethamine, bromfenac, prednisolone PO4, gatifloxacin, amniotic cytokine extract (ACE), prostaglandin E2 (PGE2), and combinations thereof.

This disclosure relates to a drug delivery system comprising an intraocular pressure lowering agent, a neurotrophic agent, such as a CNTF compound, a C-type Natriuretic Peptide (CNP) compound, a Tie-2 agonist, a Natriuretic Peptide Receptor-B (NPR-B) compound, or an apoptosis signaling fragment inhibitor (FAS) or FAS-ligand (FASL) inhibitor, including any combination of these compounds and a sustained delivery component. Methods of treating a glaucoma or related conditions, medicaments, kits, uses and methods of manufacturing are also described.

The present disclosure relates to a drug delivery system comprising an intraocular pressure-lowering agent, a neurotrophic agent such as a CNTF compound, a C-type natriuretic peptide (CNP) compound, a Tie-2 agonist, a natriuretic peptide receptor B (NPR-B) compound, or an apoptosis signaling fragmentation inhibitor (FAS) or FAS ligand (FASL) inhibitor (including any combination of these compounds), and a sustained-delivery component. Methods, medicaments, kits, methods of use, and methods of manufacture for treating glaucoma or related conditions are also disclosed. [Selection diagram] None

Provided herein are compounds comprising a formula of 4-(3- amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-y I) benzyl adamantane carboxylate (e.g., compounds of formula (I) ) or a pharmaceutically acceptable salt thereof. The compounds are useful for reducing intraocular pressure and for treating glaucoma or ocular hypertension. Formula (I).

The present application relates to a nitric oxide donor-type compound and use thereof in the preparation of a medicament for preventing and / or treating ophthalmic diseases such as glaucoma and ocular hypertension. The compound has a structure represented by formula (I), or is a stereoisomer, tautomer, solvate, metabolite, pharmaceutically acceptable salt, or prodrug of the structure represented by formula (I).

To provide ophthalmic devices and methods for treating glaucoma, ocular hypertension (OHT), and other diseases. [Solution] The system (20) comprises a radiation source (48) and a controller (44), the controller being configured to: display a live sequence of images of the patient's (22) eye (25); while displaying the sequence of images of the eye, to direct the radiation source to irradiate the eye with one or more targeting beams (84) visible in the images; after directing the targeting beams to the eye with the radiation source, to receive confirmation input from the user; and in response to receiving confirmation input, to treat the eye by directing the radiation source to irradiate each target area of ​​the eye with multiple treatment beams. Other embodiments are also described.

Antibodies that specifically bind to TrkB and methods for using the same are described. Neuroprotective agonist antibodies are described, as indicated by their effect on enhancing the survival of retinal ganglion cells in vitro, and these agonist antibodies may be used to treat eye disorders, such as glaucoma. Additionally, other neuronal diseases or disorders, including those characterized by partial neuronal damage, benefit from treatment using these agonist antibodies. In certain embodiments, the present invention comprises antibodies that bind to TrkB and mediate cell signaling. The antibodies of the present invention may be whole human, non-natural antibodies formulated as injectable excipients.

A system for performing ophthalmic treatment includes a surgical microscope configured to capture a surface image of an eye of a patient; and an imaging device mounted on the surgical microscope and configured to capture a tomographic image of an eye of a patient. A controller is coupled with the surgical microscope and the imaging device, the controller configured to receive the surface image and the tomographic image and to provide feedback based on the tomographic image and the surface image to facilitate an ophthalmic treatment. Feedback may involve avoiding capsular bag rupture during phacoemulsification, safely performing retinal membrane dissection, IOL implantation, treating glaucoma, or performing other ophthalmic treatments.

Devices and methods to remove trabecular meshwork to treat glaucoma and other conditions which may not utilize cutting elements when stripping the trabecular meshwork. The trabeculorhexis parts tissue by applying non-cutting shear and tension to the tissue to disinsert the tissue from its attachments. Reducing or eliminating the need for sharp cutting implements in the eye reduces the likelihood of incisional bleeding, iris and scleral tissue maceration and further inadvertent tissue damage of the gonio structure of the eye. In another aspect, a cutting element may be used to form a circumferential slit in a wall of Schlemm's canal in conjunction with removal of trabecular meshwork or independently.

The current invention relates to a retainer provided with an annular intraocular drug delivery device for use in the treatment of glaucoma, said annular intraocular drug delivery device for use in the treatment of glaucoma having an inner circumference and an outer circumference, said retainer comprising: a retainer body at least partially closed off by a retainer cap, said retainer cap being configured to support said annular intraocular drug delivery device for use in the treatment of glaucoma, and a retainer slider, being displaceable perpendicular to the longitudinal axis of the retainer body, characterized in, that said retainer cap at least supports said inner circumference of said annular intraocular drug delivery device for use in the treatment of glaucoma.

A method of treating glaucoma in an eye includes obtaining a surgical instrument having a cutting means and severing / cleaving an anterior attachment of a portion of trabecular meshwork of the eye proximate to Schwalbe's line with the cutting means while leaving the ciliary muscle tendons attached to the scleral spur of the portion of trabecular meshwork to create a trabecular meshwork leaflet. The surgical instrument including the cutting means is preferably a handheld microsurgical cutting instrument having at least one sharpened edge. Alternatively, the instrument may be an invasive or non-invasive laser cutting instrument with a laser cutting means; a vibratory cutting instrument with a vibratory cutting means; or a thermal cutting instrument with a thermal cutting means. The step of severing the portion of trabecular meshwork is preferably characterized by a linear cleavage plane severing the attachment portion without removing substantially any trabecular meshwork from the eye.

Devices and methods to remove trabecular meshwork to treat glaucoma and other conditions which may not utilize cutting elements when stripping the trabecular meshwork. The trabeculorhexis parts tissue by applying non-cutting shear and tension to the tissue to disinsert the tissue from its attachments. Reducing or eliminating the need for sharp cutting implements in the eye reduces the likelihood of incisional bleeding, iris and scleral tissue maceration and further inadvertent tissue damage of the gonio structure of the eye. In another aspect, a cutting element may be used to form a circumferential slit in a wall of Schlemm's canal in conjunction with removal of trabecular meshwork or independently.

The present disclosure relates generally to the treatment of glaucoma and / or the reduction of elevated intraocular pressure (IOP). In particular, the present disclosure relates to compositions and methods for preventing or treating glaucoma, including primary glaucoma, by inhibiting factors associated with ocular lymphangiogenesis.

Provided herein are compositions and formulations for alleviating problems associated with unregulated intraocular pressure (IOP) in an eye comprising the administration of Trabodenoson. Administration of Trabodenoson results in reversing or blocking disease progression of glaucoma and other related disorders. Trabodenoson also restores functionality of the pressure sensor in an eye.

This invention relates to an ophthalmic method and apparatus for the treatment of glaucoma. It provides an apparatus and method of illuminating a microcatheter tip either by using green light for optimised visualisation, blue light to stimulate fluorescence or IR light in conjunction with a dye for angiography of vascular structures the light produced by an LED coupled to an optical fibre. Laser focussing optics is used and back scatter through the fibre is monitored. The backscatter information is used to automatically signify priming of the microcatheter with a fluid or signal changes in a fluid pump function or multiple fluid deliveries through a single microcatheter. Furthermore, the backscatter information offers the potential for automatic dispensation of fluids with or without operator intervention.

To provide a glaucoma treatment device.SOLUTION: A glaucoma treatment device includes a plurality of microporous layers arranged together so as to form a microporous body configured to facilitate an evacuation of fluid from a fluid-filled body cavity and reabsorption of drained aqueous humor by the body through tissue surrounding the glaucoma treatment device. In some examples, the glaucoma treatment device includes one or more portions configured to resist cellular internal growth and one or more portions configured to allow the cellular internal growth. Especially, the outside thereof may comprise or be defined by one or more membranes, where the membranes are porous or otherwise permeable to the fluid of the fluid-filled body cavity.SELECTED DRAWING: Figure 1

The present invention relates to pharmaceutical composition comprising the beta 1 (β1)-receptor blocker timolol and a liquid vehicle comprising a semifluorinated alkane. The pharmaceutical composition of the present invention may be useful for topical administration, for example ophthalmic topical administration and for use in the treatment of glaucoma, increased intraocular pressure, ocular hypertension and / or a symptom associated therewith.

A bypass device is implanted into a body tissue via a minimally invasive surgery to provide fluid channels through the body tissue. The bypass device includes a base portion having opposite first and second ends, and flexed tines attached to the base portion configured in a flexed position relative to the base portion. The base portion includes flow spaces present from where the flexed tines are flexed relative to the base portion, the flow spaces permitting fluid flow through the bypass device. The bypass device further includes an anchor tine located adjacent to the second end of the base portion that aids in securing the bypass device in place after implantation. The bypass device may be implanted in the eye using a MIGS procedure for the treatment of glaucoma, whereby aqueous humor is permitted to flow through the flow spaces of the bypass device.

Heteroaromatic compounds are provided which are allosteric modulators of the cannabinoid receptors and which are useful for the treatment of glaucoma, pain, neuropathic pain, post-traumatic stress disorder (PTSD), and neurodegenerative diseases such as Huntington's disease, Alzheimer's disease, Parkinson's disease, multiple sclerosis, and other diseases where cannabinoid receptors are involved.

The present invention provides ophthalmic dual and triple compound medicine compositions for treating glaucoma and ocular hypertension. Through a salt modification technology, stability of the medicine compositions is improved remarkably. The dual compound medicine composition is prepared from netarsudil free alkali or pharmaceutically acceptable salts of the same and a β-adrenergic receptor blocker. The triple compound medicine composition is prepared from the netarsudil free alkali or the pharmaceutically acceptable salts of the same, the β-adrenergic receptor blocker and a prostaglandin analog. The dual and triple compound medicine compositions have excellent stability when pH is in a range from 4.5 to 5.4, an effective dose of the medicine composition of the present invention is applied to eyes of a patient in need once a day at bedtime or close to bedtime, an intra-ocular pressure can be reduced efficiently and quickly, the intra-ocular pressure remains in a physiological range for a longer time, side effects are minor, and patient compliance is high.

The present invention provides implantable devices for controlling fluid outflow from the anterior chamber of the eye, kits containing them, and methods for using them in the treatment of glaucoma.

Embodiments disclosed herein are directed to fixed compositions comprising brimonidine and timolol for lowering intraocular pressure and treating glaucoma.

This invention discloses an extracellular vesicle derived from Gastrodia elata, its preparation method, and its use in preparing drugs for treating glaucoma, belonging to the field of biomedical technology. This invention claims protection for an extracellular vesicle prepared from dried Gastrodia elata. The extracellular vesicles provided by this invention have no significant cytotoxicity and good biocompatibility. Studies have shown that these extracellular vesicles can significantly inhibit apoptosis of R28 cells and loss of Brn3a⁺ cells in the mouse retina in a glutamate excitotoxicity model. In a glaucoma model, these extracellular vesicles can effectively protect the survival of retinal ganglion cells (RGCs) and retinal function, and can significantly reduce retinal neuroinflammatory responses in the glaucoma model. Therefore, the extracellular vesicles provided by this invention have a clear anti-glaucoma-related retinal damage effect and possess great potential for development into drugs for treating glaucoma.